Pfizer Stock (NYSE:PFE)
After a medical magazine reported Phase 2 data showing the weight reduction benefits of the Pfizer (NYSE:PFE) oral GLP-1 receptor agonist danuglipron, Pfizer stock increased by almost 4%, marking the greatest intraday gain since October. This was the first time since October that the rise was this large during the trading day.
The findings, published on the JAMA Network on Monday, represent a complete readout of a corporate presentation on danuglipron at a medical conference in September of the previous year.
The researchers highlighted that a twice-daily regimen of danuglipron, which is a possible competitor to Novo Nordisk’s (NVO) famous obesity medicine Wegovy, resulted in a statistically significant weight reduction when compared to a placebo. This weight loss occurred with the danuglipron treatment.
In the trial, there were a total of 411 people with type 2 diabetes who were given either a placebo or danuglipron, which is also known as PF-06882961, twice daily for 16 weeks at approximately 100 different research locations across the world.
Regarding the least squares mean difference, the researchers discovered that individuals who got danuglipron at doses of 120 mg and 80 mg twice daily lost 4.17 and 2.04 kilograms of weight, respectively, compared to those who were given a placebo.
Among the most frequent adverse effects reported, nausea, diarrhea, and vomiting were the most prevalent. “The researchers found that the safety and efficacy profile of danuglipron was in line with the peptidic GLP-1R agonists and without fasting restrictions,” referring to the pharmacological class that the therapy belongs to.
Meanwhile, Novo Nordisk (NVO) said on Monday that an oral form of its GLP-1 receptor agonist semaglutide resulted in a weight reduction of 15.1% when administered at a dosage of 50 mg.
Featured Image: Megapixl
Author Shariq Khan 
